Heat Biologics (HTBX) Plans Presentation ofTopline HS-110 + Opdivo Phase 1b Study in NSCLC at Upcoming Conference
Tweet Send to a Friend
Heat Biologics, Inc. (Nasdaq: HTBX) announced that it will be reporting topline results from the Phase Ib study evaluating HS-110 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
